How to Buy Royalty Pharma Stock
Royalty Pharma PLC
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
Royalty Pharma stock last closed at $32.82, up 0.34% from the previous day, and has increased 18.48% in one year. It has overperformed other stocks in the Biotechnology industry by 0.95 percentage points. Royalty Pharma stock is currently +36.47% from its 52-week low of $24.05, and -4.04% from its 52-week high of $34.20.
As of Apr 30, 2025, there are 576.45M RPRX shares outstanding. The market capitalization of RPRX is $18.92B. In the past 24 hours, 4.55M RPRX shares were traded.
How to Buy Royalty Pharma Stock
Not sure how to invest in Royalty Pharma stock? Here's how.
- Decide where to buy Royalty Pharma stock: You need to choose an online brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you determine where to buy Royalty Pharma stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit money your investment account: Choose your payment method and add your details.
- Analyze Royalty Pharma stock: The Royalty Pharma ticker symbol is RPRX. Is Royalty Pharma stock a good investment? Should you buy shares of RPRX? How do RPRX's underlying business fundamentals look? Do top analysts think Royalty Pharma is a good buy? Why has RPRX's stock price moved recently? (Hint: Our stock research tools can help you understand if RPRX is a good stock to buy).
- Execute your RPRX purchase: Decide if you will purchase RPRX shares at the current market price or use a limit order to purchase RPRX stock at a given price.
- Keep tabs on your RPRX position: Create a watchlist to get the latest news on your new investment in Royalty Pharma stock.
Step 1: Decide where to buy Royalty Pharma stock
You will need a brokerage account in order to access the NASDAQ market and buy RPRX shares.
Our recommended brokerage: eToro
In our opinion, eToro is the best place to buy stocks. Here's why:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world financial markets: From Tech to Energy, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected the right brokerage, you need to fill out some personal information so you are able to buy RPRX today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to start your new brokerage account.
- Send your data by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you've created your account on the highest rated app to buy and sell stocks, you can securely and quickly fund your account:
Check out the walkthrough below for more details depositing funds into your new investment account.
Step 4: Analyze Royalty Pharma stock
After you have identified the best place to buy Royalty Pharma stock, it's critical to research their stock before you buy, so you truly understand the risk as well as the upside.
Overview of key RPRX info
Royalty Pharma Overview
WallStreetZen was designed to help everyday investors do better fundamental analysis in less time.
You can view all of the due diligence checks on RPRX's stock page.
How is RPRX stock valued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge RPRX's fair value.
Using relative valuations metrics:
- RPRX could be undervalued based on its P/E ratio of 17.09x, relative to Biotechnology industry P/E ratio of -162.28x
- RPRX could be undervalued based on its P/B ratio of 1.83x, relative to Biotechnology industry P/B ratio of 4.45x
- RPRX could be undervalued based on its PEG ratio of 0.3x
You can access additional valuation analysis on RPRX's stock here.
RPRX Financial Summary
Passed Financial Due Diligence Checks:
- There are more short-term assets than short-term liabilities on the RPRX balance sheet.
- Total RPRX debt is lower than 5 years ago, relative to shareholder equity.
- RPRX's operating cash flow of $2.77B allows it to safely service it's debt of $7.61B.
Failed Financial Due Diligence Checks:
- RPRX earnings of $1.08B is not sufficient to cover its interest payments.
- There are more long-term liabilities than short-term assets on the RPRX balance sheet.
- RPRX has a relatively high debt to equity ratio of 0.76.
- RPRX profit margin has gone down from 48.2% to 37.9% in the past year.
You can dig deeper into what analysts are projecting on the Royalty Pharma stock forecast page.
RPRX Technicals
RPRX Performance Metrics
Last year, RPRX earnings were $858.98M. During the last four year, RPRX's earnings have grown by 9.82% per year. This was slower than the Biotechnology industry average of 10.4%.
Last year, RPRX revenue was $2.26B. In the last five year, RPRX's revenue has increased by 4.52% per year. This was slower than the Biotechnology industry average of 45.66%.
Find out more about RPRX's earnings and revenue performance here.
Latest Insiders Trades at RPRX
Over the past 12 months, insiders at RPRX have bought more shares than they have sold.
Bonnie L. Bassler, Director of RPRX, was the latest RPRX insider to buy. They bought $37,500.11 worth of RPRX stock on Mar 31, 2025.
Learn more about who owns RPRX shares here.
Does RPRX provide a stable income stream?
Royalty Pharma pays a dividend of 1.31%, compared to the Biotechnology industry's average dividend yield of 1.92%. If you owned $1,000 of RPRX stock, you would have received $13.10 in the past year.
Royalty Pharma dividend payments have consistently grown over the past 5 years and have remained stable.
Find more info about Royalty Pharma dividend yield and history here.
Get opinions from other traders
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Execute your RPRX purchase
You have two main options:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are usually sufficient. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a specific dollar amount limit, use a limit order.
Press the Open button and your broker will place your order.
If you require additional help investing in stocks on eToro, watch the how to video below:
Step 6: Keep tabs on your RPRX position
Now that you own some RPRX stock, you'll want to keep up with your new investment.
Add RPRX to a watchlist to get the latest updates about your RPRX stock.
RPRX Feed
How to Buy Stock in Royalty Pharma
To summarize, here are the 6 steps to buy Royalty Pharma stock:
- Decide where to buy Royalty Pharma stock
- Create your brokerage account
- Deposit money your investment account
- Analyze Royalty Pharma stock
- Execute your RPRX purchase
- Keep tabs on your RPRX position
If you require a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you want to track your new investment in Royalty Pharma, get started below.
Related Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.